These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27021324)

  • 41. Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.
    Durani U; Tosh PK; Barreto JN; Estes LL; Jannetto PJ; Tande AJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4914-8. PubMed ID: 26055378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.
    Liu K; Wu D; Li J; Chen H; Ning H; Zhao T; Dai H; Chen L; Mangin E; Winchell GA; Waskin H; Jiang J; Qiu Y; Zhao XM
    Adv Ther; 2020 May; 37(5):2493-2506. PubMed ID: 32319040
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.
    Jang SH; Colangelo PM; Gobburu JV
    Clin Pharmacol Ther; 2010 Jul; 88(1):115-9. PubMed ID: 20505665
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity.
    Mitsani D; Nguyen MH; Shields RK; Toyoda Y; Kwak EJ; Silveira FP; Pilewski JM; Crespo MM; Bermudez C; Bhama JK; Clancy CJ
    Antimicrob Agents Chemother; 2012 May; 56(5):2371-7. PubMed ID: 22330924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.
    Fortún J; Muriel A; Martín-Dávila P; Montejo M; Len O; Torre-Cisneros J; Carratalá J; Muñoz P; Fariñas C; Moreno A; Fresco G; Goikoetxea J; Gavaldá J; Pozo JC; Bodro M; Vena A; Casafont F; Cervera C; Silva JT; Aguado JM;
    Liver Transpl; 2016 Apr; 22(4):427-35. PubMed ID: 26709146
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.
    Guarascio AJ; Slain D
    Pharmacotherapy; 2015 Feb; 35(2):208-19. PubMed ID: 25644669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
    J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.
    Walravens J; Brouwers J; Spriet I; Tack J; Annaert P; Augustijns P
    Clin Pharmacokinet; 2011 Nov; 50(11):725-34. PubMed ID: 21973269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pharmacokinetics of posaconazol in the prophylaxis and treatment of invasive fungal infection in immunocompromised children in a pediatric hospital].
    Valenzuela R; García P; Barraza M; Palma J; Catalán P; Santolaya ME; Torres JP; Morales J
    Rev Chilena Infectol; 2018; 35(1):15-21. PubMed ID: 29652967
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies.
    Cojutti PG; Candoni A; Lazzarotto D; Rabassi N; Fanin R; Hope W; Pea F
    Br J Clin Pharmacol; 2018 Nov; 84(11):2544-2550. PubMed ID: 29975796
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men.
    Krishna G; Parsons A; Kantesaria B; Mant T
    Curr Med Res Opin; 2007 Mar; 23(3):545-52. PubMed ID: 17355736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.
    Kohl V; Müller C; Cornely OA; Abduljalil K; Fuhr U; Vehreschild JJ; Scheid C; Hallek M; Rüping MJ
    Antimicrob Agents Chemother; 2010 Jan; 54(1):207-12. PubMed ID: 19858252
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
    Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
    Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis.
    Bryant AM; Slain D; Cumpston A; Craig M
    Int J Antimicrob Agents; 2011 Mar; 37(3):266-9. PubMed ID: 21236645
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.
    Mattiuzzi G; Yilmaz M; Kantarjian H; Borthakur G; Konopleva M; Jabbour E; Brown Y; Pierce S; Cortes J
    J Infect Chemother; 2015 Sep; 21(9):663-7. PubMed ID: 26141814
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication.
    Elkayal O; Spriet I; Uyttebroeck A; Colita A; Annaert P; Allegaert K; Smits A; Van Daele R; Dreesen E
    Ther Drug Monit; 2021 Aug; 43(4):512-518. PubMed ID: 33560094
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability.
    Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
    Ther Drug Monit; 2017 Apr; 39(2):93-101. PubMed ID: 28282366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection.
    Kim JH; Benefield RJ; Ditolla K
    Mycoses; 2016 Nov; 59(11):726-733. PubMed ID: 27392814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.
    Gross BN; Ihorst G; Jung M; Wäsch R; Engelhardt M
    Pharmacotherapy; 2013 Oct; 33(10):1117-25. PubMed ID: 23864486
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.
    Kersemaekers WM; Dogterom P; Xu J; Marcantonio EE; de Greef R; Waskin H; van Iersel ML
    Antimicrob Agents Chemother; 2015; 59(6):3385-9. PubMed ID: 25824210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.